SANTA CRUZ BIOTECHNOLOGY, INC.

HHV-8 K8.1A (2A3): sc-65445



XBACKGROUND

HHV-8, also designated Kaposi's sarcoma-associated herpesvirus, is associated with multicentric Castleman's disease and primary effusion lymphoma, a rare type of non-Hodgkin lymphoma affecting the body cavities. The HHV-8 K8.1 gene encodes for two immunogenic/lytic glycoproteins that are generated by a splicing event: K8.1A and K8.1B. K8.1A is the predominant form associated with the virion envelope and is comprised of 228 residues. This protein consists of a cleavable signal sequence, a transmembrane domain, 0-glycosylation sites and four N-glycosylation sites. Evidence suggests that K8.1A interacts with heparan sulfate (HS) molecules on the surface of target cells and could mediate HHV-8 interaction with HS. The K8.1B glycoprotein has 167 residues, is similar in sequence to K8.1A but it contains a 61 residue in frame deletion. In addition, K8.1B has only three N-glycosylation sites and lacks 0-glycosylation sites.

REFERENCES

- Chandran, B., et al. 1998. Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. Virology 249: 140-149.
- Zhu, L., et al. 1999. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology 256: 381-392.
- Zhu, L., et al. 1999. Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies. Virology 262: 237-249.
- Wu, L., et al. 2000. Human herpesvirus 8 glycoprotein K8.1: expression, post-translational modification and localization analyzed by monoclonal antibody. J. Clin. Virol. 17: 127-136.
- Tedeschi, R., et al. 2001. A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. Br. J. Cancer. 84: 122-125.
- Wang, FZ., et al. 2001. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. J. Virol. 75: 7517-7527.
- Luna, RE., et al. 2004. Kaposi's sarcoma-associated herpesvirus glycoprotein K8.1 is dispensable for virus entry. J. Virol. 78: 6389-6398.
- 8. Jessop, S., et al. 2006. HIV-associated Kaposi's sarcoma. Dermatol Clin. 24: 509-520.
- 9. He, F., et al. 2007. Human herpesvirus 8: serovprevalence and correlates in tumor patients from Xinjiang, China. J. Med. Virol. 79: 161-166.

SOURCE

HHV-8 K8.1A (2A3) is a mouse monoclonal antibody raised against HHV-8 K8.1A .

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 200 $\mu g~lg G_{2a}$ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

HHV-8 K8.1A (2A3) is recommended for detection of HHV-8 K8.1A of viral origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of HHV-8 K8.1A: 62 kDa.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.